Cosmin Alexandrescu, president of the Professional Association of Outpatient Doctors
♦ Mounjaro, America's obesity product from Eli Lilly, increased its sales 60 times in the 4th quarter of 2025 versus Q4/2024 and passed 30 million euros in the last three months of 2025 ♦ Family doctor: «It's a phenomenon, I found out from a pharmacist that many of my patients take anti-obesity treatments. When I asked them, they confirmed it» ♦ Four out of ten Romanians suffer from obesity, according to statistics ♦ Across the ocean, in America, one in eight people has already used a slimming product.
An obesity medicine, Mounjaro, increased its sales in Romania more than 60 times in Q4 of 2025 versus the same quarter of 2024, up to 30 million euros. Annual sales for this product can exceed 100-120 million euros, according to ZF's calculations based on market research. The spectacular increase comes against the background of an increasing number of Romanians suffering from obesity, four out of ten people having this condition. «It's a phenomenon, I learned from a pharmacist with whom I collaborate that many of my patients take anti-obesity treatments. When I asked them, they confirmed it,» said doctor Gindrovel Dumitra, family doctor, vice-president of the National Society of Family Medicine. One in eight Americans has already used a weight-loss drug that appeared on the market in recent years, and by 2030 the number will increase and one in five Americans will use these products, writes the Financial Times. «In the case of slimming drugs, here, on the one hand, the modern lifestyle, the ultra-processed diet, the large portions, both in stores and in restaurants, lead to obesity. I think it is the biggest obesity epidemic in history at the moment», said doctor Cosmin Alexandrescu, president of the Professional Association of Outpatient Physicians (APMA).
For other news, analyses, articles and business information in real time, follow NV on WhatsApp Channels